Chagas Disease (American Trypanosomiasis) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Chagas Disease (American Trypanosomiasis) – Drugs In Development, 2024 report and make more profitable business decisions.
Chagas disease, or American trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting, and swollen glands. Treatment includes antiparasitic medications.
The Chagas Disease (American Trypanosomiasis) drugs in development market research report provide comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Chagas Disease (American Trypanosomiasis) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Chagas Disease (American Trypanosomiasis) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Chagas Disease (American Trypanosomiasis) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Chagas Disease (American Trypanosomiasis) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
7 Hills Pharma LLCAN2 Therapeutics Inc
AstraZeneca Plc
Cesa Alliance SA
Collaborations Pharmaceuticals Inc
ConserV Bioscience Ltd
Daiichi Sankyo Co Ltd
Diakonos Research Ltd
Drugs for Neglected Diseases initiative
Eisai Co Ltd
Flanders Institute for Biotechnology
Fox Chase Chemical Diversity Center Inc
Ghent University
GSK plc
Helmholtz Center Munich German Research Center for Health and Environment GmbH
Helmholtz Centre for Infection Research
McGill University Health Center
Novartis AG
NYU Langone Health System
Oblita Therapeutics BVBA
Pasteur Institute
RIKEN
Sanofi
Selva Therapeutics Inc
Synstar Japan Co Ltd
University of Bologna
University of California San Francisco
University of Dundee
University of Texas at El Paso
University of Valencia
University of Washington
Vanderbilt University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Chagas Disease (American Trypanosomiasis) reports